Why the study?
To explore the causal associations between 91 circulating inflammatory proteins and ICM, DCM, and HCM to provide insight into heart failure mechanisms, diagnosis, and drug targets.
Do genetically predicted levels of circulating inflammatory proteins causally affect the risk of ischemic, dilated, or hypertrophic cardiomyopathy heart failure?
Comparison
91 circulating inflammatory proteins vs ICM, DCM, and HCM
Design
Two-sample Mendelian randomization study
Authors
Loading...
May highlight inflammatory targets across cardiomyopathy subtypes; leaves open clinical translation pending prospective validation.
Do genetically predicted levels of circulating inflammatory proteins causally affect the risk of ischemic, dilated, or hypertrophic cardiomyopathy heart failure?
Specific circulating inflammatory proteins exhibit distinct causal relationships with ischemic, dilated, and hypertrophic cardiomyopathies, highlighting potential novel biomarkers and therapeutic targets.
Rui et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: